During Tuesday’s current trade, FedEx Corporation (NYSE:FDX)’s shares gained2.90%, and is now trading at $171.50.
Today, FedEx Corporation (FDX), and TNT Express will host a press conference today at 09:30 hours CET at the Amsterdam Hilton Apollolaan.
FedEx Corporation (FDX), and TNT Express N.V. (Euronext Amsterdam: TNTE) declared that they have reached a conditional contract (the Merger Protocol) on a recommended all-cash offer for all issued and outstanding ordinary shares, counting shares represented by American Depositary Receipts (the Shares) of TNT Express (the Offer) for a cash offer price of €8.00 per share cum dividend except for the TNT Express final 2014 dividend of €0.08 (the Offer Price) in a transaction valuing TNT Express at an implied equity value of about €4.4 billion ($4.8 billion).
FedEx Corporation: provides transportation, e-commerce, and business services in the United States and internationally. The corporation’s FedEx Express segment provides various shipping services for the delivery of packages and freight; international trade services specializing in customs brokerage, and ocean and air freight forwarding services; international trade advisory services, such as assistance with the customs-trade partnership against terrorism program; and customs clearance services, in addition to global trade data, an information tool that allows customers to track and manage imports.
In an afternoon trade, Axalta Coating Systems Ltd (NYSE:AXTA)’s shares climbed 7.31%, and is now trading at $30.40, today, Axalta Coating Systems (AXTA), declared that an associate of Berkshire Hathaway Inc. (“Berkshire Hathaway”) has entered into a definitive stock purchase contract with certain associates of The Carlyle Group (“Carlyle”) for the purchase of a total of 20 million of Axalta’s ordinary shares for an aggregate purchase price of $560 million, or $28.00 per share. Axalta will not receive proceeds from the sale of the shares. In connection with the purchase, Berkshire Hathaway agreed that it would not dispose of the shares for 90 days following the consummation of the sale.
Axalta Coating Systems Ltd:, through its auxiliaries, manufactures, markets, and distributes high performance coatings products primarily for the transportation industry. It operates through two segments, Performance Coatings and Transportation Coatings. The Performance Coatings segment offers various waterborne and solvent borne products and systems that are used to refinish damaged vehicles for independent body shops, multi-shop operators, and original equipment manufacturer (OEM) dealership body shops.
Ocular Therapeutix Inc (NASDAQ:OCUL), during its Tuesday’s current trading session dipped -9.14%, and is now trading at $34.99, after Ocular Therapeutix Inc (OCUL), declared top line data from the Corporation’s second of two Phase 3 clinical trials evaluating the safety and efficacy of its lead product candidate, OTX-DP (Sustained Release Dexamethasone, 0.4mg), for the treatment of ocular inflammation and pain following cataract surgery and stated additional details from the first Phase 3 clinical trial. The two primary efficacy endpoints for the OTX-DP Phase 3 clinical trials were statistically noteworthy differences between the treatment group and the placebo group for the absence of pain on day 8 and absence of inflammatory cells on day 14. Both endpoints need to be met for the trials to be considered successful. In the second Phase 3 clinical trial, OTX-DP met one of the study’s two primary efficacy endpoints. In this trial, 77.5% of patients receiving OTX-DP stated an absence of pain in the study eye on day 8 following insertion of the drug product, contrast to 58.8% of those receiving placebo vehicle control punctum plug, a difference which was statistically noteworthy(p=0.0025). 39.4% of OTX-DP-treated patients showed an absence of inflammatory cells in the anterior chamber of the study eye on day 14 following drug product insertion, contrast to 31.3% of those receiving placebo vehicle control punctum plug , a difference which was not statistically noteworthy(p=0.2182). Additionally, there were a total of 240 patients enrolled in the second clinical trial, with a 2:1 randomization of treated and control patients.
Ocular Therapeutix, Inc: a biopharmaceutical corporation focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the United States.
Cheetah Mobile Inc (ADR) (NYSE:CMCM)’s shares jumped 15.92% during the current trading session Tuesday, and is now trading at $24.68, as Cheetah Mobile Inc (ADR) (CMCM), declared that it has signed a commercial contract with Nanigans, Inc. (“Nanigans”), a leading worldwide provider of social and mobile advertising software and pioneer in advertising automation software. The commercial contract comes in conjunction with Cheetah Mobile’s recent planned investment as the lead investor in Nanigans US$24 million Series B financing.
Mr. Sheng Fu, Chief Executive Officer of Cheetah Mobile, stated, “We are happy to declare this business partnership with Nanigans. Nanigans plays an important role in the social and mobile advertising ecosystem, as evidenced by its strong customer base. Investing in Nanigans advertising automation software is a noteworthystep for us, as we actively build up our advertising platform and enhance our capabilities globally. We look forward to this deeper cooperation with the Nanigans team and we are confident in our ability to create the world’s first-class tools for advertisers and publishers.”
Cheetah Mobile Inc: operates a platform that offer mission critical applications for its users and global content distribution channels for its business partners in the Peoples Republic of China. The corporation’s mission critical applications optimize Internet and mobile system performance and provide real time protection against known and unknown security threats.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
